Controversies in the management of advanced prostate cancer by Tyrrell, C J
Prostate cancer is one of the most common forms of cancer in men
and, after lung cancer, is the most common cause of male cancer
death (Figure 1). The incidence of prostate cancer varies around
the world and is highest in Western countries such as the USA and
Scandinavia (Parker et al, 1997). In the USA, the incidence and
prevalence of prostate cancer is increasing, with an estimate
(based on deaths from 1979 to 1993) of 334 000 new cases and
41 800 deaths for 1997 (Parker et al, 1997; Wingo et al, 1997). The
incidence of prostate cancer in Japan, although low at one-tenth of
North America, is also rising rapidly, perhaps because of adoption
of a more Westernized lifestyle (Dearnaley, 1994).
Prostate cancer is rarely diagnosed before the age of 50 and the
incidence increases markedly between the ages of 60 and 80 years,
with a median age at diagnosis of 72 years (Brawley and Kramer,
1994). As the male population over 75 years increases, so too do
the number of men at risk from prostate cancer.
Prostate cancer growth is stimulated by androgens, principally
testosterone, therefore androgen deprivation is an essential
component in the treatment of this disease. Advanced prostate
cancer is usually defined as a disease which has become metastatic
or locally advanced, and is, therefore, incurable. Traditional treat-
ment for advanced prostate cancer is castration (surgical or
medical) which reduces serum testosterone levels by about 90%
(Labrie et al, 1985; Lunglmayr et al, 1988). However, castration
does not affect androgen biosynthesis in the adrenal glands and
addition of an anti-androgen may be used to block the effect of
remaining testosterone on the prostate cells. The addition of anti-
androgen to castration is commonly known as combined androgen
blockade (CAB) or maximal androgen blockade (MAB).
This review will discuss the relative advantages and disadvan-
tages of hormonal treatments available for advanced prostate
cancer (Table 1), with particular emphasis on CAB. Related treat-
ment options and additional factors in the selection of treatment
will also be reviewed.
MAIN HORMONAL TREATMENTS AVAILABLE
First-line hormonal treatment of advanced prostate cancer is either
castration alone or in combination with an anti-androgen. This
section reviews surgical castration, medical castration and anti-
androgens, followed by their use in combination therapy (CAB).
Surgical castration (orchidectomy)
Bilateral orchidectomy, either total or subcapsular, has been the
mainstay of treatment for advanced prostate cancer and is the
comparator against which other treatments are assessed.
Orchidectomy produces symptom relief in 70–80% of patients
(Kaisary et al, 1991), and provides pain relief from symptoms of
bone metastases in 80–90% of patients. The size of the prostate
tumour shrinks within 4–6 weeks of orchidectomy (Paulson, 1981).
Because testosterone levels are reduced so quickly, orchidectomy is
often the best treatment for men with metastases in the spine who
are at severe risk of paralysis (Korman, 1989). If a surgical option
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is not possible, then ketoconazole can be used to lower testosterone
levels very rapidly (Lowe and Bamberger, 1990).
Surgical castration is a relatively simple, safe and inexpensive
operation which can be performed under local or light general
anaesthesia (Geller et al, 1988; Griffiths et al 1993). Although the
convenience of a ‘one-off’ procedure, as opposed to medical
therapy, means patient compliance is not a problem, surgical
castration is not acceptable to all patients (Catalona, 1994), mainly
because of psychological trauma (Cassileth et al, 1992; Denis,
1993; Fossa et al, 1994). The trauma of castration can be avoided
to some extent by use of the subcapsular technique which removes
only the functional part of the testicle.
Disadvantages of orchidectomy include loss of libido, impo-
tence and hot flushes (Varenhorst, 1993), which occur in around
60% of men. A further disadvantage is that the operation is irre-
versible. Patients with non-hormone responsive prostate cancer
may, therefore, have undergone unnecessary surgery. If intermit-
tent androgen blockade proves beneficial (see later), then
orchidectomy may not be the best treatment option because of its
irreversibility.
Orchidectomy reduces circulating testosterone by around 90%
(Labrie et al, 1985). However, the intraprostatic concentration of
the active androgen, dihydrotestosterone (DHT), after castration is
less affected and may amount to 30–40% of normal levels (Labrie
et al, 1987; Geller et al, 1988). This residue must be derived from
adrenal androgens which make a sizeable contribution to androgen
metabolism within the prostate gland.
Medical castration
Luteinizing hormone-releasing hormone (LH-RH)
analogues
LH-RH analogues provide one method of medical castration and
are a widely used alternative to surgical castration. LH-RH,
produced by the hypothalamus, stimulates production of
Table 1 Hormone therapies for advanced prostate cancer: advantages and disadvantages
Treatment Advantages Disadvantages
Orchidectomy Symptom relief Does not eliminate adrenal androgens
Rapid reduction in circulating testosterone Psychological trauma
No compliance problems Irreversible
Loss of libido
Impotence
Medical castration
Luteinizing hormone-releasing As effective as orchidectomy without Does not eliminate adrenal androgens
hormone (LH-RH) analogues surgery Risk of tumour flare
(e.g. leuprolide, goserelin Reversible Loss of libido
acetate, buserelin) Low risk of cardiovascular side-effects Impotence
Longer acting formulations, e.g. goserelin
acetate 12-week depot
Diethylstilboestrol (DES) As effective as orchidectomy, without Risk of cardiovascular complications
surgery Loss of libido
Gynaecomastia
Nausea
Anti-androgens
Steroidal (e.g. cyproterone Avoids surgery Loss of libido
acetate) As effective as oestrogens Impotence
Disturbances in liver function
Thromboembolism
Steroidal effects, e.g. fluid retention
Non-steroidal Blocks action of dihydrotestosterone and Diarrhoea (incidence with flutamide twice
(e.g. flutamide, bicalutamide, testosterone that with bicalutamide)
nilutamide) Reduces risk of testosterone flare Liver toxicity (flutamide)
Avoids surgery Visual problems (nilutamide only)
Most commonly used in combination with Alcohol intolerance (nilutamide only)
surgical or medical castration (CAB)
Less cardiovascular toxicity than DES Gynaecomastia
Preservation of potency in 75% of men Hot flushes
Lung
Prostate
Colon + rectum
Pancreas
Leukaemia
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Figure 1 Reported cancer deaths in men (USA, 1993, from Parker et al,
1997)luteinizing hormone (LH) from the pituitary gland. Testosterone is
produced by the testes in response to LH. Negative feedback
occurs via the rise in testosterone levels, which brings about a
decrease in hypothalamic release of LH-RH. The continuous infu-
sion of LH-RH analogues renders the pituitary refractory to hypo-
thalamic regulation, thus suppressing the release of androgen from
the testes. Goserelin acetate, buserelin, leuprolide and triptorelin
have all been administered as LH-RH analogues (e.g. Labrie et al,
1985; Crawford et al, 1989). All have similar modes of action and
efficacy and plasma testosterone levels are reduced to castrate
levels within 2–4 weeks of starting the treatment. Both leuprolide
and goserelin acetate have been shown to be as effective as
diethylstilboestrol (DES), with objective responses of 50–85% for
DES and 70–86% for the LH-RH analogues (Leuprolide Study
Group, 1984; Emtage et al, 1988). However, goserelin acetate has
superior tolerability to DES (Emtage et al, 1988). Only goserelin
acetate has been shown, in major comparative studies, to be equiv-
alent to surgical castration on the basis of the degree of serum
testosterone suppression, objective response rates (71% vs 72%),
duration of response (53.7 vs 50.1 weeks) and survival (27.5 vs
24.8 months; Debruyne et al, 1988; Kaisary et al, 1991). In a
comparison of the effects of surgical castration and goserelin
acetate treatment on patients’ quality of life (QOL), a significant
improvement in two scores of QOL were observed in patients
treated with goserelin acetate, but not in those who had surgical
castration (Cassileth et al, 1992).
A variety of routes of administration are available for LH-RH
analogues and ease of administration may be the deciding factor in
the choice of agent. Buserelin is given initially by subcutaneous
injection three times daily, then intranasally six times daily, with
obvious problems of compliance. The inconvenience of daily
injections and the uncertainty of intranasal administration has been
overcome by the introduction of biodegradable depot formulations
which provide controlled release of LH-RH analogue over a
prolonged period. Goserelin acetate, leuprolide and triptorelin are
all available as monthly intramuscular or subcutaneous injections.
Goserelin acetate is now also available in a 12-weekly depot
preparation for subcutaneous injection (Dijkman et al, 1995;
Debruyne et al, 1996a), and leuprolide is also available as a 3-
month depot in some countries (Fernandez Del Moral et al, 1996).
These controlled-release preparations have obvious advantages in
terms of patient compliance and acceptability.
As expected of an LH-RH agonist, the initial administration
may cause a temporary rise in testosterone, which may account for
the worsening of symptoms, particularly bone pain, seen in up to
5% of patients (Brewster and Gillatt, 1993; Bruchovsky et al,
1993; Dijkman et al, 1995). This flare phenomenon can have
potentially serious effects in patients with spinal secondaries,
precipitating spinal cord compression and resulting in paraplegia.
Treatment with an anti-androgen 7–10 days before, or concomi-
tantly with, the first injection of LH-RH analogue can prevent the
surge of serum testosterone and control the exacerbation of symp-
toms (Boccon-Gibod et al, 1986; Kuhn et al, 1989; Tyrell et al,
1991). With continued LH-RH analogue treatment, serum testos-
terone falls to castrate levels and no rise is seen with subsequent
injections (Bruchovsky et al, 1993; Brogden and Faulds, 1995).
LH-RH analogues are generally well tolerated: the main side-
effects are similar to surgical castration, i.e. loss of libido, impo-
tence and hot flushes (Varenhorst, 1993). Libido and impotence
occur in most men treated with LH-RH analogues or surgical
castration, whereas hot flushes occur in about 60% of patients
(Kaisary et al, 1991; Denis et al, 1993).
Oestrogens
For many years, DES was the only hormonal alternative to
orchidectomy. Oestrogens produce their effect partly by
suppressing the secretion of LH-RH from the hypothalamus,
thereby inhibiting the release of LH from the pituitary, resulting in
castrate levels of testosterone, and partly by directly opposing the
action of androgens on prostate cells. However, the use of high-
dose oestrogens was associated with significant mortality and
morbidity because of cardiovascular complications (in up to 25%
of patients), including increased incidence of thromboembolism
and fluid retention (Veterans Administration Co-operative
Urological Research Group, 1967; Allvizatos and Oosterhof,
1993). This led to their use in the treatment of prostate cancer
being greatly reduced in the 1970s.
In Scandinavia, oestrogens are still an acceptable therapy for
prostate cancer; the drugs commonly used are estramustine phos-
phate or ethinyl oestradiol in combination with polyestradiol phos-
phate (Henriksson and Edhag, 1986; Lundgren et al, 1986, 1995).
As a primary treatment, estramustine phosphate is reported to be
as effective as conventional antineoplastic agents in the treatment
of advanced prostate cancer (Perry and McTavish, 1995). As a
second-line treatment, estramustine phosphate is no more effective
after bilateral orchidectomy than placebo (Iversen et al, 1997a;
Janknegt et al, 1997).
Recent investigations using high-dose intramuscular-depot
oestrogen (estradurin) indicate that cardiovascular side-effects
may be lower with this method of administration than with oral
administration (Stege et al, 1995). In addition, parenteral adminis-
tration of polyestradiol phosphate may have bone preserving
capacity in patients with prostate cancer (Carlstrom et al, 1997).
Further studies by the Scandinavian Prostatic Cancer Group are
ongoing and results from a study (SPCG 5) involving over 900
patients on the efficacy and tolerability of parenterally adminis-
tered polyestradiol phosphate compared with decapeptyl plus
flutamide are due to be analysed in 1998.
Recently, there has been increased interest in the use of low-
dose oestrogens. Low-dose DES (1 mg day–1) was found to be as
effective as orchidectomy and associated with fewer malignant
disease-related deaths than the more conventional higher dose
(3 mg or more). However, it was associated with slightly more
deaths (16 out of 108 patients) due to cardiovascular causes than
orchidectomy (9 out of 108 patients) (Robinson, 1993). If the risk
of cardiovascular toxicity could be controlled, then oestrogens
may become a more acceptable option in the management of
prostate cancer.
Other
Used in high doses, ketoconazole causes castrate levels of testos-
terone within 24–48 h and, therefore, has been assessed to deter-
mine its role in the treatment of advanced prostate cancer (Lowe
and Bamberger, 1990). One clear indication for its use is for treat-
ment of men with metastases of the spine who require a prompt
therapeutic response (Bamberger and Lowe, 1988). Other indica-
tions include: when orchidectomy is contraindicated, when oestro-
gens are contraindicated, initial empirical therapy, and hormonally
refractory disease. It can also be used in conjunction with LH-RH
analogues. However, ketoconazole can cause liver toxicity and
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minimize toxicity (Small et al, 1997a, 1997b). Ketoconazole is
useful for short-term treatment, but is not particularly useful for
long-term therapy (Lowe and Bamberger, 1990).
Anti-androgens
Anti-androgens act by competitively blocking the binding of
testosterone, and its metabolite DHT, to nuclear receptors in
prostate cancer cells (Neumann and Jacobi, 1982) and may be
steroidal or non-steroidal.
The main steroidal anti-androgen cyproterone acetate (CPA) has
been used as oral monotherapy in advanced prostate cancer. This
drug reduces testosterone to near castrate levels by its progesto-
genic effect, suppressing LH-RH and LH. CPA is typically given
in a dosage of 200–300 mg day–1 in two or three divided doses, and
has been shown to be as effective as oestrogen in terms of objec-
tive response (40% vs 55%), rate of progression (52% vs 47%) and
overall survival (Pavone-Macaluso et al, 1986). Equivalence with
surgical castration or LH-RH analogues has not been demon-
strated. CPA reduces libido and potency in around 86% of men, a
similar incidence to that of surgical and medical castration
(Barradell and Faulds, 1994). Other side-effects of CPA include
changes in body weight, fatigue, disturbances in liver function
(Ohri et al, 1991; Drakos et al, 1992; Watanabe et al, 1994) and
thromboembolism (Barradell and Faulds, 1994). CPA has also
been evaluated in combined therapy (refer to CAB section).
Non-steroidal anti-androgens, such as nilutamide, flutamide
and bicalutamide, have been evaluated for both monotherapy
(discussed here) and for combined therapy (discussed in the CAB
section) in patients with advanced prostate cancer. The efficacy of
nilutamide and flutamide as monotherapy has only been investi-
gated in small non-comparative studies. Only one study showed
equal mean time to progression between monotherapy and
orchidectomy; in a comparison of flutamide (250 mg three times
daily) and orchidectomy involving 104 patients, at the 24-month
follow-up, mean time to progression was similar in each group
(320 vs 352 days, P = 0.49; Boccon-Gibod et al, 1994).
Bicalutamide monotherapy has been evaluated in much larger
trials than those carried out for other anti-androgens. Such studies,
therefore, are more likely to show up small differences between
treatments. A combined analysis of more than 1000 patients
showed that bicalutamide monotherapy (50 mg once daily) had a
higher treatment failure rate (53% vs 41%), higher objective
progression (46% vs 35%) and lower survival (25 vs 28 months, P
= 0.0001) compared with castration (Bales and Chodak, 1996)
demonstrating that although bicalutamide is an effective anti-
androgen, it is not equivalent to castration at a dose of 50 mg.
Although statistically significant, the clinical significance is open
to interpretation. In addition, in two of these trials the survival
difference was not significant.
A combined analysis of two multicentre randomized trials
comparing bicalutamide 150 mg once daily with castration
(goserelin acetate or orchidectomy) showed a survival benefit for
castration in metastatic patients, but the survival difference was
only 6 weeks (Tyrrell et al, 1996). In addition, the dose of 150 mg
had an identical tolerability to the 50-mg dose. In patients with
non-metastatic disease (M0), preliminary results suggest that
bicalutamide 150 mg may prove equivalent to castration in terms
of survival (Tyrrell et al, 1996; Iversen et al, 1997b).
When the patient’s QOL, tolerability of treatment and sexual
function are considered, bicalutamide, either 50 mg or 150 mg,
provides significantly better symptom relief, a better QOL and
greater preservation of sexual interest compared with castration
(Bales and Chodak, 1996; Tyrrell et al, 1996). Higher doses of
bicalutamide for use as monotherapy are currently being investi-
gated (Kaisary, 1997).
The non-steroidal anti-androgens obviously do not have the
steroidal events associated with CPA. For non-steroidal anti-
androgens used as monotherapy, loss of libido and potency is
reported in only 20–30% of men (Decensi et al, 1991; Kaisary,
1994), compared with 86% for CPA. As a class, non-steroidal anti-
androgens are associated with side-effects such as gynaecomastia
(around 40–62% of patients affected), hot flushes (23–50%) and
breast pain (26–63%), however there are differences in the side-
effect profiles of flutamide, nilutamide and bicalutamide which are
unrelated to their anti-androgenic properties.
Nilutamide is associated with a high incidence (20%) of
reversible visual abnormalities (Boccardo et al, 1991; Decensi et
al, 1991). Approximately one-fifth of patients treated with nilut-
amide experience alcohol intolerance (Decensi et al, 1991), a
problem not reported with any other anti-androgens. Reversible
pulmonary interstitial lung disease has been reported with an inci-
dence of approximately 1% in patients treated with nilutamide
(Pfitzenmeyer et al, 1992). Nilutamide is not currently available in
the UK.
Flutamide monotherapy is associated with a much higher inci-
dence of diarrhoea (29%, Narayan et al, 1996; 20%, Delare and
Van Thillo, 1991; 9%, Chang et al, 1996) than bicalutamide
monotherapy (2.5%, Kaisary, 1994; 1.9%, Lunglmayr and the
International Casodex Study Group, 1995). Raised liver enzymes
have been noted in up to 32% of patients after flutamide treatment
(Lundgren, 1987). Serious hepatotoxicity has been reported at an
annual rate of 3 per 10 000 flutamide users (Wysowski et al, 1993,
Wysowski and Foureroy, 1996). Of 19 cases of serious hepato-
toxicity reported to the US Food and Drug Administration (FDA)
over a 3-year period, five died of progressive liver disease
(Wysowski et al, 1993).
Bicalutamide is associated with a lower incidence of side-
effects than other anti-androgens. In clinical studies, the incidence
of adverse hepatic events, such as raised liver enzymes, during
bicalutamide therapy is low (Tyrrell, 1992; Kaisary et al, 1996),
and to date there have been no reports of fatal hepatic adverse
effects of bicalutamide (Kolvenbag and Blackledge, 1996). Used
in combination therapy, bicalutamide was associated with signifi-
cantly less diarrhoea than flutamide (10% vs 24%; see CAB
section; Schellhammer et al, 1996a).
Combined androgen blockade (CAB)
Although LH-RH analogues offer a more acceptable method of
castration than surgery, they offer no advantage over orchidectomy
in terms of prognosis. This is because the effect of both LH-RH
analogues and orchidectomy is limited to blocking production of
testicular androgens. Addition of anti-androgens, which block the
action of androgens of testicular and adrenal origin, to medical or
surgical castration was developed to provide additional androgen
blockade (CAB) and so prolong survival of patients with advanced
prostate cancer. Bracci and colleagues were the first to utilize CAB,
combining CPA treatment with bilateral orchidectomy (Bracci and
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De Silverio, 1977; Bracci, 1979). Clinical trials suggesting the effi-
cacy of CAB using flutamide and leuprolide were first reported by
Labrie and co-workers (Labrie et al 1982, 1987).
CAB has now been compared with castration alone (medical
and surgical) in numerous clinical trials. Some trials show advan-
tage of CAB over castration whereas others report no significant
difference (Table 2). No study has reported that CAB is less effec-
tive than castration. There is, therefore, considerable debate about
the benefits of CAB over castration alone.
Three large, randomized, double-blind, controlled trials
comparing CAB with castration have demonstrated a statistically
significant improvement for CAB in time to progression and
length of survival (Crawford et al, 1989; Denis et al, 1993;
Janknegt et al, 1993, 1996). The largest of these trials (603
patients) compared CAB using daily leuprolide and flutamide with
leuprolide treatment alone (Crawford et al, 1989). Patients treated
with CAB had a longer progression-free survival (16.5 vs 13.9
months, P = 0.039) than patients treated with the LH-RH analogue
alone. Their median length of survival was also significantly
longer (35.6 vs 28.3 months, P = 0.035). A subsequent European
Organization for Research and Treatment of Cancer (EORTC) trial
including 327 patients compared CAB using goserelin acetate plus
flutamide with surgical castration (Denis et al, 1993). This trial
also demonstrated a statistically significant advantage in favour of
CAB for time to progression (33.3 vs 21.3 months, P = 0.008) and
survival (34.4 vs 27.1 months, P = 0.02). In a comparison of
orchidectomy plus nilutamide with orchidectomy alone involving
457 patients (Janknegt et al, 1993), a significant (P < 0.05) 7-
month increase in median survival, before death from cancer, and a
progression-free survival advantage of 5.9 months were observed.
Long-term follow-up (up to 8 years) also indicated significant
benefits in survival and progression-free survival (Janknegt et al,
1996). Additional studies are in progress.
A number of studies have reported equivalence for CAB and
castration. Six studies of flutamide in combination with LH-RH
analogue compared with LH-RH analogue or orchidectomy alone,
with patient numbers of 50–571, showed median times to progres-
sion of 16–32 months and median survival of 23–36 months with no
statistically significant differences between the treatment arms
(Jurincic et al, 1991; Tyrrell et al, 1991; Boccardo et al, 1993; Ferrari
et al, 1993; Fourcade et al, 1993; Iversen et al, 1993). Crawford et al
(1997) have recently reported results from a prospective, randomized
trial comparing flutamide plus orchidectomy with placebo plus
orchidectomy in 1387 patients with stage D2 prostate cancer. No
statistically significant differences between the groups were found
with respect to either time to progression (mean 21 and 18 months
respectively) or survival (mean 31 and 30 months). Similarly, studies
with nilutamide in combination with either orchidectomy or LH-RH
analogue showed no statistically significant difference in time to
progression and median survival from the castration alone treatment
(medical or surgical; Brisset et al, 1987; Knönagel et al, 1989; Béland
et al, 1990; Crawford et al, 1990; Le Duc et al, 1990; Namer et al,
1990). CPA has also been evaluated in combination therapy and there
was no significant difference in survival between CPA plus goserelin
acetate and the LH-RH analogue alone (Di Silverio et al, 1990;
Brewster et al, 1992). With the exception of the recently reported
large study by Crawford et al (1997), the individual trials reported
above generally have small numbers of patients and, therefore, do not
provide sufficient statistical power to demonstrate effect or to statisti-
cally refute the results of the three large positive trials (Trachtenberg,
1997). To determine a significant survival benefit in favour of CAB
and to ensure treatment groups are balanced, it has been estimated
Table 2 Large randomized trials of combined androgen blockade (CAB)
Anti-androgen/ Number of Trial design Time to Median Follow-up
investigator patients progression survival (months)
Flutamide
Crawford et al (1997) 1387 Orchidectomy + flutamide vs NS NS 57
orchidectomy + placebo
Crawford et al (1989, 603 Leuprolide + flutamide vs CAB superior CAB superior 42
1995) leuprolide + placebo P = 0.039 P = 0.035
Tyrrell et al (1991) 571 Goserelin + flutamide vs goserelin NS NS 24
Boccardo et al (1993) 373 Goserelin + flutamide vs goserelin NS NS 24
Denis et al (1993) 327 Goserelin + flutamide vs CAB superior CAB superior 60
orchidectomy P = 0.008 P = 0.02
Iversen et al (1993) 262 Goserelin + flutamide vs NS NS 57
orchidectomy
Fourcade et al (1993) 245 Goserelin + flutamide vs goserelin NS NS 48
+ placebo
Nilutamide
Janknegt et al (1993, 457 Orchidectomy + nilutamide vs CAB superior CAB superior 76–102
1996) orchidectomy + placebo P = 0.005 P = 0.041
Crawford et al (1990) 333 Leuprolide + nilutamide vs NS NS NR
leuprolide + placebo
Cyproterone acetate
Brewster et al (1992) 349 Goserelin + CPA vs goserelin NS NS NR
Di Silverio et al (1990) 328 Goserelin + CPA vs goserelin NS NS 9–58
De Voogt et al (1990) 307 Buserelin + CPA vs orchidectomy NS NS 12
Robinson (1993) 221 Orchidectomy + CPA vs NS NS 48
orchidectomy
NS, no significant difference; NR, data not reported; goserelin, goserelin acetate.Management of advanced prostate cancer 151
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that it is necessary to include at least 300 patients per treatment arm
(Van Tinteren and Dalesio, 1993). The lack of a sufficiently long
follow-up period or even a lack of a clear end point, such as survival,
were also important factors (Denis, 1995; Trachtenberg, 1997).
Interim analyses based on too short a follow-up period can result in
too few patients being followed to disease progression to make defi-
nite conclusions. Meta-analyses, pooling the results of all studies, is
one method to overcome some of these problems.
Meta-analyses, however, also differ on whether CAB shows
benefit over castration. A meta-analysis of the individual data
from 22 randomized, controlled trials involving 5710 patients
treated with either castration (medical or surgical) or various
forms of CAB showed a non-significant difference in survival
(Prostate Cancer Trialist’s Collaborative Group, 1995). Five-year
survival rates were 26.2% in the CAB group and 22.8% in the
conventional therapy group (these rates are currently being re-
evaluated). The Ontario Cancer Treatment Practice Guidelines
Initiative suggested that there were a number of methodological
weaknesses in the above meta-analysis. These included: the
absence of an initial protocol document; no detailed description of
search strategy and inclusion/exclusion criteria; no assessment of
the quality of the trials, particularly unpublished studies; and
the inclusion of data on patients with non-metastatic disease. The
authors also noted that a statistically significant difference
favouring CAB would have been produced if a one-sided t-test
(testing the hypothesis that CAB is of benefit or neutral), rather
than a two-sided test had been used. Consequently, they conducted
a sensitivity analysis of the randomized trials (Klotz and Newman,
1996). An analysis based only on published data (20 studies)
demonstrated that therapy with CAB was associated with a clear
benefit of 2 years additional survival over castration alone. In
addition, the meta-analysis of the Prostate Cancer Trialist’s
Collaborative Group (1995) was criticized for grouping results of
trials that used both steroidal and non-steroidal anti-androgens and
the use of immature data (Labrie and Crawford, 1995; Quartey,
1995; Waxman and Pandha, 1995).
An earlier meta-analysis of seven randomized, double-blind
trials (1191 patients), which compared CAB (orchidectomy plus
nilutamide) with orchidectomy plus placebo in patients who had
received no previous hormonal treatment, showed significant
delay to disease progression in the nilutamide group compared
with the placebo group (Bertagna et al, 1994). Nilutamide used in
combination therapy resulted in a statistically significant reduction
in risk of progression (16%, P = 0.05) and a non-significant 10%
reduction in the risk of death. In an update of this analysis, after a
further 2-year follow-up, the reduction in risk of progression was
maintained (17%, P = 0.031, Debruyne et al, 1996b). The risk of
death from cancer was reduced by 16% (P = 0.053). A smaller,
meta-analysis of selected trials showed a statistically significant
benefit for CAB (Caubet et al, 1996).
Some studies reported a high incidence of withdrawal because
of the side-effects of flutamide (Boccardo et al, 1990; Tyrrell et al,
1991; Boccon-Gibod et al, 1992). This may have skewed the
results in favour of castration alone, particularly in those trials
which did not employ a placebo. It is clear, however, that the toler-
ability and comparative efficacy of the various anti-androgens
should be considered when choosing which anti-androgen to use
in CAB treatment.
Only one study has compared anti-androgens in the context of
CAB. The study compared treatment with bicalutamide plus LH-
RH analogue with flutamide plus LH-RH analogue in 813 patients
with untreated metastatic (stage D2) prostate cancer
(Schellhammer et al, 1996a–1996c, 1997; Soloway et al, 1996). At
the latest follow-up (median duration 160 weeks), there was an
improvement in time to treatment failure with bicalutamide plus
LH-RH analogue, although this was non-significant. In terms of
survival at 160 weeks, 53% of patients in the bicalutamide group
died compared with 57% in the flutamide group. The median
survival time was 180 weeks for the bicalutamide group compared
with 148 weeks for the flutamide group. The incidence of treat-
ment-related diarrhoea was significantly higher in the flutamide
group (26% vs 12%, P < 0.001) and caused more treatment with-
drawals (25) than in the bicalutamide group (two) (Schellhammer
et al, 1997). Diarrhoea has been reported with similar incidence in
other flutamide CAB studies (Crawford et al, 1989; Tyrrell et al,
1991). The incidence of diarrhoea in the Crawford study, irrespec-
tive of relation to therapy, was reported to the FDA Advisory
Committee meeting as 23.8% for the flutamide group and 11.2%
for placebo (Schellhammer et al, 1996d). Episodes of diarrhoea in
flutamide-treated patients have been of sufficient intensity to
require withdrawal from therapy in 2–10% of patients (Boccardo
et al, 1990; Iversen et al, 1990; Tyrell et al, 1991).
Other factors, such as the stage and extent of disease, can also
influence the outcome of CAB treatment. The study by Crawford
et al (1989) shows that patients with minimal metastatic disease
(defined as five or fewer hotspots on bone scan) and good perfor-
mance status, who received combined therapy of leuprolide and
flutamide, had improved median time to progression compared
with patients who received LH-RH analogue alone (48 months vs
19.1 months). Their overall survival was lengthened by 20 months
(Crawford et al, 1995). The EORTC meta-analysis, although it had
small subgroups, indicated that patients with fewer than five bone
metastases and good performance status tended to benefit most
from CAB (Denis et al, 1993).
In summary, the overall results of a large number of studies
suggest that CAB is at least equivalent to conventional therapy in
terms of time to progression and survival. However, opinion is
divided on whether CAB has an additional beneficial effect over
conventional therapy. CAB’s demonstrated equivalence and strong
therapeutic rationale suggest that it could be a primary treatment
option in advanced prostate cancer. In the absence of a statistically
significant difference in the effectiveness of available anti-
androgens in CAB, selection may be based on factors such as
tolerability. In this respect, bicalutamide may have benefits over
flutamide.
RELATED TREATMENT OPTIONS
Intermittent therapy
The proposal that prostate cancer cells adapt to androgen depriva-
tion and grow more rapidly in the presence of androgen blockade
has resulted in the development of intermittent therapy. The idea is
that the patient is treated with androgen blockade until prostate-
specific antigen (PSA) is in the normal range, then treatment is
stopped until there is evidence of further tumour development (a
rise in PSA) when treatment can be started again. It is hypothesized
that after the period of androgen exposure (no anti-androgen
therapy) the cells will remain sensitive to androgen deprivation and
react a second time to anti-androgens rather than progressing to
become hormone insensitive. It may not be necessary, therefore, for
all patients with limited disease to stay on therapy indefinitely, as152 CJ Tyrrell
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some patients could have intermittent androgen blockade.
Preliminary clinical data indicate that this approach is feasible and
may offer benefits in terms of QOL and preservation of sexual
function (Goldenberg et al, 1995). A randomized prospective study
(by the Southwest Oncology Group, SWOG) and an open, non-
randomized study (by the European Organization for Research and
Treatment of Cancer, EORTC) are currently under way to assess
further the value and feasibility of intermittent therapy.
Withdrawal
There have been several recent reports of favourable clinical and
PSA responses to the withdrawal of non-steroidal anti-androgens
in patients with progression of disease after lengthy remission
while taking CAB (Dupont et al, 1993; Kelly and Scher, 1993;
Scher and Kelly, 1993; Nieh, 1995). Scher and Kelly (1993) found
that in patients who relapsed while receiving combination therapy
of LH-RH analogue and flutamide, if the anti-androgen alone was
stopped, the patients went back into remission, some for as long as
2 years. This was not only subjective remission with a falling PSA,
but, in those patients with measurable lesions, there was also
evidence of objective remission. This withdrawal response is seen
in up to 30% of patients, almost exactly the same proportion of
patients who respond to single-agent chemotherapy after relapse
on hormone therapy. The mechanism for this withdrawal effect is
unknown, but it may be related to the development of cancer cell
clones that have mutated to be dependent on the anti-androgen as a
substrate.
ADDITIONAL FACTORS IN SELECTION OF
TREATMENT OPTIONS
Patients are increasingly involved in decisions about treatment and
physicians need to consider the requirements and preferences of
individual patients when evaluating treatment options. Physicians
both under- and overestimate their patients’ subjective morbidity
and impact of symptoms on QOL (Osoba, 1994; Calais da Silva et
al, 1996). Improvement of QOL and symptom control has become
a major end point in clinical trials of prostate cancer (Fossa, 1996).
The following issues are relevant to improved QOL of patients
with advanced prostate cancer: bone pain, micturition, sexuality,
vitality, hot flushes and gynaecomastia. As these factors may be of
equal importance to the patient as length of survival, QOL results
will need to be incorporated into the overall evaluation of treat-
ment together with survival and health economic considerations.
In studies of patient choice, 78–86% of patients preferred medical
castration with the LH-RH analogue goserelin acetate to orchidec-
tomy (Lunglmayr and Girsh, 1987; Cassileth et al, 1989; Fossa et al,
1994). The main motives for choosing LH-RH analogues were
avoidance of surgery (36%), success of treatment (18%) and conve-
nience of drug treatment (10%). The reversibility of treatment with
goserelin acetate if ineffective was the primary or secondary reason
for choosing the drug for 50% of urologists. The primary reasons for
patients choosing surgical castration were the convenience of
surgical procedure (32%) and success of treatment (29%).
The stage and grade of the disease and the timing of treatment
may also give an indication of the success of a particular treatment
option. CAB may be more beneficial in minimal disease patients
(Crawford et al, 1989; Denis et al, 1993). Disease progression
occurs more rapidly and the chance of developing serious compli-
cations is increased in patients who receive delayed hormonal
treatment compared with those who receive immediate treatment
(Kirk, 1996).
Patient compliance is another factor to be considered in selec-
tion of treatment for prostate cancer. Compliance is influenced by
factors such as efficacy, tolerability and complexity and conve-
nience of the dosing regimen. Differences between the anti-andro-
gens in respect of dosing regimen and tolerability may result in
different rates of compliance (Kaisary, 1996). For example, once-
daily dosing regimens are associated with significantly better
compliance than regimens involving three or four daily doses
(Greenberg, 1984). The long elimination half-life of bicalutamide
(approximately 7 days; Cockshott et al, 1990) enables once-daily
dosing and offers an advantage over anti-androgens with shorter
elimination half-lives and more frequent dosing regimens. The
active metabolite of flutamide, hydroxyflutamide, has a half-life of
4.3–6.6 h (Brogden and Clissold, 1989) and the drug requires three
times daily dosing. Nilutamide, with a half-life of 23–87 h permits
once-daily dosing (Harris et al, 1993).
CONCLUSIONS
Surgical castration is the main hormone treatment for advanced
prostate cancer against which other treatments are assessed,
although medical castration is an acceptable alternative. CAB
combines the benefits of medical or surgical castration with effec-
tive blockade of adrenal androgens. The results of clinical trials so
far show that CAB is at least equivalent to conventional therapy in
terms of survival and progression-free survival. However, opinion
is divided on whether CAB has an additional beneficial effect over
conventional therapy in advanced prostate cancer. The choice of
components for CAB is dependent on the efficacy and tolerability
of the various treatments and patient preference. In terms of choice
of anti-androgen, bicalutamide may be associated with a lower
incidence of side-effects compared with the other non-steroidal
anti-androgens and may offer CAB with a lower risk of discontin-
uation because of intolerance.
Hormonal agents for treating advanced prostate cancer represent
a wide range of treatment options. Physicians and patients need to
determine the most appropriate option for a given patient based on
factors such as the staging extent of the disease, the patient’s
performance status and the patient’s requirements in terms of QOL
and survival.
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